JP2014522846A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014522846A5 JP2014522846A5 JP2014519165A JP2014519165A JP2014522846A5 JP 2014522846 A5 JP2014522846 A5 JP 2014522846A5 JP 2014519165 A JP2014519165 A JP 2014519165A JP 2014519165 A JP2014519165 A JP 2014519165A JP 2014522846 A5 JP2014522846 A5 JP 2014522846A5
- Authority
- JP
- Japan
- Prior art keywords
- bispecific
- biopharmaceutical
- lag
- ctla
- ligand specific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000011087 biopharmaceutical technology Methods 0.000 claims 12
- 102100019451 CD80 Human genes 0.000 claims 7
- 101700080477 CD80 Proteins 0.000 claims 7
- 102100017213 LAG3 Human genes 0.000 claims 6
- 108060004270 LAG3 Proteins 0.000 claims 6
- 230000027455 binding Effects 0.000 claims 6
- 239000003446 ligand Substances 0.000 claims 6
- 102100005310 CTLA4 Human genes 0.000 claims 5
- 101700054183 CTLA4 Proteins 0.000 claims 5
- 230000035772 mutation Effects 0.000 claims 4
- 102000004965 antibodies Human genes 0.000 claims 3
- 108090001123 antibodies Proteins 0.000 claims 3
- 102200015631 BANF1 R75E Human genes 0.000 claims 2
- 102220387255 H4C7 R75A Human genes 0.000 claims 2
- 102220432771 RPS13 W84A Human genes 0.000 claims 2
- 102200051612 ZP3 E196A Human genes 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 102200048937 ABHD17A S190A Human genes 0.000 claims 1
- 102200055099 DEXI S201A Human genes 0.000 claims 1
- 101710030615 GALNT9 Proteins 0.000 claims 1
- 102200017880 GJA3 R76K Human genes 0.000 claims 1
- 102200029236 MGME1 M81A Human genes 0.000 claims 1
- 102200018422 PLA2G2A R73E Human genes 0.000 claims 1
- 102200045955 QKI N97A Human genes 0.000 claims 1
- 102220432051 YES1 K71G Human genes 0.000 claims 1
- 102200053863 YWHAZ R63A Human genes 0.000 claims 1
- 229960000074 biopharmaceuticals Drugs 0.000 claims 1
Claims (13)
- リンカーにより隔置されるＣＴＬＡ−４に特異的なリガンドおよびｐＭＨＣ複合体に特異的なリガンドを含む二重特異性バイオ医薬品。
- ＣＴＬＡ−４に特異的なリガンドはＣＴＬＡ−４に特異的な抗体、およびＣＤ８０（Ｂ７−１）またはＣＤ８６（Ｂ７−２）から選択される、請求項１に記載の二重特異性バイオ医薬品。
- ｐＭＨＣ複合体に特異的なリガンドは抗ＭＨＣ抗体およびＬＡＧ−３から選択される、請求項２に記載の二重特異性バイオ医薬品。
- リンカーはポリアミノ酸配列および抗体Ｆｃドメインのうちの１つまたはそれ以上である、請求項１に記載の二重特異性バイオ医薬品。
- ポリアミノ酸配列はＧ９（Ｇｌｙ−９）である、請求項４に記載の二重特異性バイオ医薬品。
- ＣＴＬＡ−４に特異的なリガンドはＣＤ８０である、請求項２に記載の二重特異性バイオ医薬品。
- ＣＤ８０はＣＴＬＡ−４に対する特異性を増加させるように変異される、請求項６に記載の二重特異性バイオ医薬品。
- ＣＤ８０は変異Ｗ８４Ａ、Ｋ７１Ｇ、Ｋ７１Ｖ、Ｓ１０９Ｇ、Ｒ１２３Ｓ、Ｒ１２３Ｄ、Ｇ１２４Ｌ、Ｓ１９０Ａ、Ｓ２０１Ａ、Ｒ６３Ａ、Ｍ８１Ａ、Ｎ９７ＡおよびＥ１９６Ａのうちの少なくとも１つを含むヒトＣＤ８０である、請求項７に記載の二重特異性バイオ医薬品。
- ＣＤ８０はヒトＣＤ８０の変異Ｗ８４ＡまたはＥ１９６Ａを含む、請求項８に記載の二重特異性バイオ医薬品。
- ＭＨＣ複合体に特異的なリガンドはＬＡＧ−３である、請求項３に記載の二重特異性バイオ医薬品。
- ＬＡＧ−３はｐＭＨＣＩＩに対する特異性を増加させるように変異される、請求項１０に記載の二重特異性バイオ医薬品。
- ＬＡＧ−３は変異Ｒ７３Ｅ、Ｒ７５Ａ、Ｒ７５ＥおよびＲ７６Ｅのうちの少なくとも１つを含むヒトＬＡＧ−３である、請求項１１に記載の二重特異性バイオ医薬品。
- ＬＡＧ−３は変異Ｒ７５ＡまたはＲ７５Ｅを含む、請求項１２に記載の二重特異性バイオ医薬品。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161503282P | 2011-06-30 | 2011-06-30 | |
| US61/503,282 | 2011-06-30 | ||
| PCT/US2012/045017 WO2013003761A1 (en) | 2011-06-30 | 2012-06-29 | Inhibitors of t-cell activation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017043440A Division JP6530436B2 (ja) | 2011-06-30 | 2017-03-08 | Ｔ細胞活性化の阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014522846A JP2014522846A (ja) | 2014-09-08 |
| JP2014522846A5 true JP2014522846A5 (ja) | 2015-07-30 |
| JP6157461B2 JP6157461B2 (ja) | 2017-07-05 |
Family
ID=47424568
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014519165A Active JP6157461B2 (ja) | 2011-06-30 | 2012-06-29 | Ｔ細胞活性化の阻害剤 |
| JP2017043440A Active JP6530436B2 (ja) | 2011-06-30 | 2017-03-08 | Ｔ細胞活性化の阻害剤 |
| JP2019091790A Active JP6826154B2 (ja) | 2011-06-30 | 2019-05-15 | Ｔ細胞活性化の阻害剤 |
| JP2021003877A Pending JP2021073216A (ja) | 2011-06-30 | 2021-01-14 | Ｔ細胞活性化の阻害剤 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017043440A Active JP6530436B2 (ja) | 2011-06-30 | 2017-03-08 | Ｔ細胞活性化の阻害剤 |
| JP2019091790A Active JP6826154B2 (ja) | 2011-06-30 | 2019-05-15 | Ｔ細胞活性化の阻害剤 |
| JP2021003877A Pending JP2021073216A (ja) | 2011-06-30 | 2021-01-14 | Ｔ細胞活性化の阻害剤 |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US9834604B2 (ja) |
| EP (2) | EP3357511B1 (ja) |
| JP (4) | JP6157461B2 (ja) |
| KR (1) | KR20140058532A (ja) |
| CN (2) | CN107988156B (ja) |
| AU (3) | AU2012275133B2 (ja) |
| BR (1) | BR112013033661A2 (ja) |
| CA (1) | CA2839462A1 (ja) |
| CL (1) | CL2013003725A1 (ja) |
| CO (1) | CO6841996A2 (ja) |
| CR (1) | CR20130661A (ja) |
| DK (2) | DK3357511T3 (ja) |
| DO (1) | DOP2013000313A (ja) |
| ES (2) | ES2694749T3 (ja) |
| GT (1) | GT201300323A (ja) |
| HK (1) | HK1258401A1 (ja) |
| HR (1) | HRP20181786T1 (ja) |
| HU (1) | HUE040455T2 (ja) |
| LT (1) | LT2726101T (ja) |
| MA (1) | MA35280B1 (ja) |
| MX (1) | MX354922B (ja) |
| MY (1) | MY180616A (ja) |
| NI (1) | NI201300140A (ja) |
| PE (1) | PE20141469A1 (ja) |
| PL (2) | PL2726101T3 (ja) |
| PT (2) | PT2726101T (ja) |
| RS (1) | RS57996B1 (ja) |
| RU (1) | RU2657440C2 (ja) |
| SG (1) | SG10201604715VA (ja) |
| SI (1) | SI2726101T1 (ja) |
| TN (1) | TN2013000532A1 (ja) |
| UA (1) | UA116191C2 (ja) |
| WO (1) | WO2013003761A1 (ja) |
| ZA (1) | ZA201309532B (ja) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202323302A (zh) | 2010-11-30 | 2023-06-16 | 日商中外製藥股份有限公司 | 細胞傷害誘導治療劑 |
| EP3357511B1 (en) * | 2011-06-30 | 2020-05-13 | Genzyme Corporation | Inhibitors of t-cell activation |
| US8956619B2 (en) * | 2011-10-25 | 2015-02-17 | University Of Maryland, Baltimore County | Soluble CD80 as a therapeutic to reverse immune supression in cancer patients |
| CA2894511C (en) | 2012-12-11 | 2021-12-07 | Albert Einstein College Of Medicine Of Yeshiva University | Methods for high throughput receptor:ligand identification |
| GB201311487D0 (en) * | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Bispecific molecules |
| JP6629187B2 (ja) | 2014-04-07 | 2020-01-15 | 中外製薬株式会社 | 免疫活性化抗原結合分子 |
| EA201692287A1 (ru) * | 2014-05-13 | 2017-06-30 | Чугаи Сеияку Кабушики Каиша | Антигенсвязывающая молекула, перенаправляющая т-клетки на клетки, обладающие иммуносупрессорной функцией |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| CN105296433B (zh) | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| CN116059378A (zh) | 2014-12-10 | 2023-05-05 | 明尼苏达大学董事会 | 用于治疗疾病的遗传修饰的细胞、组织和器官 |
| CN104459129A (zh) * | 2015-01-05 | 2015-03-25 | 复旦大学附属华山医院 | 一种鉴别活动性与潜伏性结核分枝杆菌感染的诊断试剂盒 |
| WO2016168771A2 (en) | 2015-04-17 | 2016-10-20 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| SG10201906059VA (en) | 2015-07-30 | 2019-08-27 | Macrogenics Inc | Pd-1-binding molecules and methods of use thereof |
| US20180256644A1 (en) * | 2015-09-14 | 2018-09-13 | Alpine Immune Sciences, Inc. | Tunable variant immunoglobulin superfamily domains and engineered cell therapy |
| TW201722985A (zh) | 2015-11-02 | 2017-07-01 | 戊瑞治療有限公司 | Cd80胞外域多肽及其用於癌症治療 |
| WO2017086419A1 (ja) | 2015-11-18 | 2017-05-26 | 中外製薬株式会社 | 液性免疫応答の増強方法 |
| EP3378487B1 (en) | 2015-11-18 | 2022-03-16 | Chugai Seiyaku Kabushiki Kaisha | Combination therapy using t cell redirection antigen binding molecule against cell having immunosuppressing function |
| EP3389714A4 (en) | 2015-12-14 | 2019-11-13 | MacroGenics, Inc. | BISPECIFIC MOLECULES HAVING IMMUNOREACTIVITY TO PD-1 AND CTLA-4 AND METHODS OF USE |
| KR101918456B1 (ko) * | 2015-12-15 | 2018-11-16 | 앱클론(주) | Cd80 및 cd86에 특이적으로 결합하는 항체 |
| WO2017106129A1 (en) | 2015-12-16 | 2017-06-22 | Merck Sharp & Dohme Corp. | Anti-lag3 antibodies and antigen-binding fragments |
| EP3192805A1 (en) | 2016-01-15 | 2017-07-19 | Humanitas Mirasole S.p.A. | Inhibitors of t cell activation or stimulation and uses thereof |
| EP3423108A4 (en) * | 2016-03-02 | 2019-10-02 | Cue Biopharma, Inc. | T CELL MODULATING MULTIPLE POLYPEPTIDES AND METHOD OF USE THEREOF |
| CN109312402A (zh) * | 2016-04-11 | 2019-02-05 | 得克萨斯州大学系统董事会 | 用于检测单个t细胞受体亲和力和序列的方法和组合物 |
| AU2017250358B2 (en) | 2016-04-15 | 2023-06-01 | Alpine Immune Sciences, Inc. | ICOS ligand variant immunomodulatory proteins and uses thereof |
| US11078282B2 (en) | 2016-04-15 | 2021-08-03 | Alpine Immune Sciences, Inc. | CD80 variant immunomodulatory proteins and uses thereof |
| IL262606B2 (en) | 2016-05-18 | 2023-04-01 | Albert Einstein College Medicine Inc | pd-l1 variant polypeptides, T-cell modulatory multimeric polypeptides, and methods of using them |
| EP3458096A4 (en) | 2016-05-18 | 2019-11-27 | Cue Biopharma, Inc. | T-LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES AND METHODS OF USE |
| US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| WO2018035710A1 (en) | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
| SI3558339T1 (sl) | 2016-12-22 | 2024-05-31 | Cue Biopharma, Inc. | Celico T modulirajoči multimerni polipeptidi in postopki njihove uporabe |
| WO2018129474A1 (en) | 2017-01-09 | 2018-07-12 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| US20200010528A1 (en) | 2017-03-15 | 2020-01-09 | Cue Biopharma, Inc. | Methods for modulating an immune response |
| CA3054068A1 (en) | 2017-03-16 | 2018-09-20 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| JP2020511144A (ja) | 2017-03-16 | 2020-04-16 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｐｄ−ｌ２バリアント免疫調節タンパク質及びその使用 |
| MX2019012849A (es) | 2017-04-28 | 2019-11-28 | Five Prime Therapeutics Inc | Metodos de tratamiento con polipeptidos del dominio extracelular del cd80. |
| KR20230020022A (ko) | 2017-10-10 | 2023-02-09 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Ctla-4 변이체 면역조절 단백질 및 이의 용도 |
| TW201925223A (zh) | 2017-10-18 | 2019-07-01 | 美商艾爾潘免疫科學有限公司 | 變異型icos 配位體免疫調節蛋白及相關組合物及方法 |
| AU2018374569B2 (en) * | 2017-11-29 | 2024-10-17 | Uti Limited Partnership | Methods of treating autoimmune disease |
| CN108003238B (zh) * | 2017-11-30 | 2021-02-02 | 常州费洛斯药业科技有限公司 | 一种能特异识别ctla-4的全人源单克隆抗体或抗体片段及其方法和用途 |
| EP3737689A4 (en) | 2018-01-09 | 2021-12-01 | Cue Biopharma, Inc. | MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF |
| JPWO2019151392A1 (ja) | 2018-01-31 | 2021-02-04 | 国立大学法人東北大学 | 抗原特異的ｍｈｃ発現調節法 |
| CN112424230A (zh) * | 2018-05-14 | 2021-02-26 | 英美偌科有限公司 | 双功能结合多肽 |
| WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
| WO2021101271A1 (ko) * | 2019-11-20 | 2021-05-27 | 주식회사 지아이셀 | T 세포 배양용 배지 조성물 및 이를 이용한 t 세포의 배양 방법 |
| KR20230009872A (ko) | 2020-05-12 | 2023-01-17 | 큐 바이오파마, 인크. | 다량체 t-세포 조절 폴리펩타이드 및 이의 사용 방법 |
| EP4211149A4 (en) | 2020-09-09 | 2024-10-09 | Cue Biopharma Inc | MHC CLASS II T-CELL MODULATING MULTIMER POLYPEPTIDES FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF |
| JP2024508207A (ja) | 2020-12-02 | 2024-02-26 | ブイアイビー ブイゼットダブリュ | がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト |
| CN114805591A (zh) * | 2022-03-31 | 2022-07-29 | 浙江大学 | 靶向ctla-4及配体cd80或cd86的双特异性抗体、筛选方法、组合物及应用 |
| WO2024036287A1 (en) * | 2022-08-12 | 2024-02-15 | Abata Therapeutics, Inc. | Stable regulatory t cells and methods of production |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5149782A (en) | 1988-08-19 | 1992-09-22 | Tanox Biosystems, Inc. | Molecular conjugates containing cell membrane-blending agents |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| DK0814159T3 (da) | 1990-08-29 | 2005-10-24 | Genpharm Int | Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| ES2241710T3 (es) | 1991-11-25 | 2005-11-01 | Enzon, Inc. | Procedimiento para producir proteinas multivalentes de union a antigeno. |
| CA2150262C (en) | 1992-12-04 | 2008-07-08 | Kaspar-Philipp Holliger | Multivalent and multispecific binding proteins, their manufacture and use |
| WO1994026087A2 (en) | 1993-05-14 | 1994-11-24 | Connor Kim C O | Recombinant protein production and insect cell culture and process |
| US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| UA71889C2 (uk) | 1996-04-02 | 2005-01-17 | Йєда Рісерч Енд Дівелопмент Ко. Лтд. | Модулятори зв'язаного з рецептором tnf фактора (traf), їх одержання та застосування |
| JP2000516101A (ja) | 1996-11-28 | 2000-12-05 | アンスティテュ ギュスタブ ルシ | Ｌａｇ−３タンパク質の変異体、その発現及び使用 |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| DK1399484T3 (da) | 2001-06-28 | 2010-11-08 | Domantis Ltd | Dobbelt-specifik ligand og anvendelse af denne |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| EP1599502A1 (en) | 2003-02-27 | 2005-11-30 | TheraVision GmbH | A molecule which binds cd80 and cd86 |
| EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
| ES2439580T3 (es) * | 2003-02-28 | 2014-01-23 | The Johns Hopkins University | Regulación de células T |
| JP2007537753A (ja) * | 2004-05-17 | 2007-12-27 | ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ | 抗原でパルスされた、二重特異性抗体（ＢｉＡｂ）でコーティングされた樹状細胞の使用 |
| EP1793858A4 (en) * | 2004-09-08 | 2008-12-10 | Univ Ohio State Res Found | HUMAN MONOCLONAL ANTI-CTLA4 ANTIBODIES FOR CANCER TREATMENT |
| BRPI0515264B1 (pt) | 2004-09-13 | 2018-12-18 | Genzyme Corp | proteína de fusão de acordo com fórmula x-y-z, composição, molécula de ácido nucleico, seus usos e método de multimerização de um polipeptídeo x |
| ES2428869T3 (es) | 2005-01-24 | 2013-11-12 | Pepscan Systems B.V. | Compuestos de unión, compuestos inmunógenos y peptidomiméticos |
| WO2008073160A2 (en) * | 2006-08-17 | 2008-06-19 | The Trustees Of Columbia University In The City Of New York | Methods for converting or inducing protective immunity |
| WO2008157367A1 (en) | 2007-06-15 | 2008-12-24 | Genzyme Corporation | Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor |
| EP2240204A1 (en) * | 2008-02-04 | 2010-10-20 | Medarex, Inc. | Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof |
| PL2257624T3 (pl) | 2008-02-05 | 2012-09-28 | Medical Res Council | Sposoby i kompozycje |
| BRPI0908496A2 (pt) | 2008-02-20 | 2019-01-15 | Genzyme Corp | inibição de angiogênese |
| AR072999A1 (es) * | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| GB0913775D0 (en) | 2009-08-06 | 2009-09-16 | Medical Res Council | Multispecific peptides |
| EP3357511B1 (en) | 2011-06-30 | 2020-05-13 | Genzyme Corporation | Inhibitors of t-cell activation |
-
2012
- 2012-06-29 EP EP18151718.6A patent/EP3357511B1/en active Active
- 2012-06-29 HU HUE12804528A patent/HUE040455T2/hu unknown
- 2012-06-29 UA UAA201400833A patent/UA116191C2/uk unknown
- 2012-06-29 CN CN201711283703.XA patent/CN107988156B/zh active Active
- 2012-06-29 CN CN201280042085.9A patent/CN103796681B/zh active Active
- 2012-06-29 SG SG10201604715VA patent/SG10201604715VA/en unknown
- 2012-06-29 ES ES12804528.3T patent/ES2694749T3/es active Active
- 2012-06-29 RS RS20181350A patent/RS57996B1/sr unknown
- 2012-06-29 JP JP2014519165A patent/JP6157461B2/ja active Active
- 2012-06-29 PE PE2013002910A patent/PE20141469A1/es active IP Right Grant
- 2012-06-29 SI SI201231438T patent/SI2726101T1/sl unknown
- 2012-06-29 PL PL12804528T patent/PL2726101T3/pl unknown
- 2012-06-29 DK DK18151718.6T patent/DK3357511T3/da active
- 2012-06-29 PT PT12804528T patent/PT2726101T/pt unknown
- 2012-06-29 WO PCT/US2012/045017 patent/WO2013003761A1/en active Application Filing
- 2012-06-29 MY MYPI2013004609A patent/MY180616A/en unknown
- 2012-06-29 DK DK12804528.3T patent/DK2726101T3/en active
- 2012-06-29 PL PL18151718T patent/PL3357511T3/pl unknown
- 2012-06-29 LT LTEP12804528.3T patent/LT2726101T/lt unknown
- 2012-06-29 EP EP12804528.3A patent/EP2726101B1/en active Active
- 2012-06-29 AU AU2012275133A patent/AU2012275133B2/en not_active Ceased
- 2012-06-29 RU RU2014102956A patent/RU2657440C2/ru not_active IP Right Cessation
- 2012-06-29 CA CA2839462A patent/CA2839462A1/en not_active Abandoned
- 2012-06-29 PT PT181517186T patent/PT3357511T/pt unknown
- 2012-06-29 BR BR112013033661A patent/BR112013033661A2/pt not_active Application Discontinuation
- 2012-06-29 ES ES18151718T patent/ES2810424T3/es active Active
- 2012-06-29 KR KR1020147002646A patent/KR20140058532A/ko not_active Application Discontinuation
- 2012-06-29 US US14/128,461 patent/US9834604B2/en active Active
- 2012-06-29 MX MX2013015384A patent/MX354922B/es active IP Right Grant
-
2013
- 2013-12-13 CR CR20130661A patent/CR20130661A/es unknown
- 2013-12-18 ZA ZA2013/09532A patent/ZA201309532B/en unknown
- 2013-12-19 NI NI201300140A patent/NI201300140A/es unknown
- 2013-12-26 TN TNP2013000532A patent/TN2013000532A1/fr unknown
- 2013-12-26 GT GT201300323A patent/GT201300323A/es unknown
- 2013-12-26 DO DO2013000313A patent/DOP2013000313A/es unknown
- 2013-12-26 CL CL2013003725A patent/CL2013003725A1/es unknown
- 2013-12-27 CO CO13301377A patent/CO6841996A2/es unknown
-
2014
- 2014-01-22 MA MA36702A patent/MA35280B1/fr unknown
-
2017
- 2017-03-08 JP JP2017043440A patent/JP6530436B2/ja active Active
- 2017-10-19 US US15/788,433 patent/US11028170B2/en active Active
- 2017-11-15 AU AU2017261541A patent/AU2017261541B2/en not_active Ceased
-
2018
- 2018-10-30 HR HRP20181786TT patent/HRP20181786T1/hr unknown
-
2019
- 2019-01-17 HK HK19100808.1A patent/HK1258401A1/zh unknown
- 2019-05-15 JP JP2019091790A patent/JP6826154B2/ja active Active
- 2019-09-09 AU AU2019226276A patent/AU2019226276B2/en not_active Expired - Fee Related
-
2021
- 2021-01-14 JP JP2021003877A patent/JP2021073216A/ja active Pending
- 2021-05-03 US US17/306,509 patent/US12043665B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014522846A5 (ja) | ||
| Shugay et al. | VDJdb: a curated database of T-cell receptor sequences with known antigen specificity | |
| MX2023006482A (es) | Anticuerpos biespecificos especificos para un receptor de tnf coestimulador. | |
| Poggi et al. | Mesenchymal stromal cells can regulate the immune response in the tumor microenvironment | |
| PH12018500766A1 (en) | Bispecific antibodies with tetravalency for a costimulatory tnf receptor | |
| MX2013011385A (es) | Moleculas de union a cd37 y sus inmunoconjugados. | |
| NZ733025A (en) | Bcma chimeric antigen receptors | |
| PE20141469A1 (es) | Inhibidores de la activacion de las celulas t | |
| TN2015000418A1 (en) | Macrocyclic inhibitors of the pd-1/pd-l1 and cd80(b7-1)/pd-l1 protein/protein interactions | |
| WO2015112626A8 (en) | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules | |
| MX2014002097A (es) | Anticuerpos bioespecificos especificos para antigenos que activan celulas t y un antigeno tumoral y metodos de uso. | |
| WO2012142343A3 (en) | Methods for providing cross-vendor support services | |
| JP2016512537A5 (ja) | ||
| TWD170834S (zh) | 互動式資訊服務系統之部分 | |
| NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| HUE037651T2 (hu) | B7-Hl-et és PD-l-et kötõ ellenanyagok és más molekulák | |
| EA201300978A1 (ru) | Антитела к сеа | |
| MX2015007745A (es) | Metodo para activar la celula t auxiliar. | |
| Markiewicz-Kijewska et al. | Antibody-mediated rejection in pediatric liver transplant recipients. | |
| JPWO2019245038A5 (ja) | ||
| Zamoyski | Warszawa 1920 | |
| MX2015004892A (es) | Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21. | |
| Klochkov et al. | Spatial structures of tripeptides glycylglycyl-l-histidine and glycylglycyl-l-tyrosine based on residual dipolar couplings and quantum-chemical computations | |
| Johnsson | Stalins mord i Katyn | |
| Wu et al. | Establishment of long-term culture system for human B cells derived from peripheral blood mononuclear cells activated via soluble CD40 ligand |